Insulet Corporation plans to raise $300m through the private placement of convertible senior notes due in 2024.

The US-based company plans to use the funds for general corporate purposes.

Hancock Jaffe Laboratories Inc has announced an initial public offering (IPO) of one million shares of its common stock priced between $6 and $8 a share to raise up to $15m.

The US-based medical device firm plans to use the stocks for research and development activities, as well as other general corporate purposes.

US-based Avinger Inc plans to raise $15m through the private placement of shares of its common stock.

The company plans to use the funds for working capital and general corporate purposes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Takeda Pharmaceutical Co Ltd has signed an agreement to develop and market Portal Instruments Inc’s needle-free drug delivery device.”

Takeda Pharmaceutical Co Ltd has signed an agreement to develop and market Portal Instruments Inc’s needle-free drug delivery device, which is planned to be used with Takeda’s investigational or approved drugs.

As part of the agreement, Takeda will make an initial payment to Portal and additional payments of up to $100m upon achieving certain development milestones.

Takeda is a Japanese pharmaceutical company, whereas Portal is a medical device company based in the US.